Pharmacological rescue of mutant ion channels

Cardiovascular Research

Volumn 55, Issue 2, 2002, Pages 229-232

  Bezzina, Connie R ^a   Tan, Hanno L ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AJMALINE; ASTEMIZOLE; CISAPRIDE; DIMETHYL SULFOXIDE; FLECAINIDE; GLYCEROL; LIDOCAINE; MEXILETINE; POTASSIUM CHANNEL; PROCAINAMIDE; PROTEIN; PROTEIN KCNE1; PROTEIN KCNE2; PROTEIN KCNH2; PROTEIN KCNJ2; PROTEIN KCNQ1; PROTEIN M1766L; PROTEIN SCN5A; SODIUM CHANNEL; UNCLASSIFIED DRUG;

BRUGADA SYNDROME; CLINICAL FEATURE; DRUG EFFECT; EDITORIAL; ELECTROCARDIOGRAPHY; GENE MUTATION; HEART DEPOLARIZATION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; PHENOTYPE; PR INTERVAL; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; QRS COMPLEX; ST SEGMENT; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; HUMANS; LONG QT SYNDROME; MEXILETINE; MUTATION; SODIUM CHANNELS;

EID: 0036065961     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00486-8     Document Type: Editorial

References (33)

1. Inherited long QT syndromes: A paradigm for understanding arrhythmogenesis
2. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome
3. Cardiac sodium channel and inherited arrhythmia syndromes
4. Brugada syndrome: Why are there multiple answers to a simple question?
5. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent
6. Expression and intracellular localization of an SCN5A double mutant R1232W/T1620M implicated in Brugada syndrome
7. Novel mechanism for Brugada syndrome: Defective surface localization of an SCN5A mutant (R1432G)
8. The Brugada syndrome: Ionic basis and arrhythmia mechanisms
9. Cardiac conduction defects associate with mutations in SCN5A
10. A sodium-channel mutation causes isolated cardiac conduction disease
11. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine
12. Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia
13. Proposed diagnostic criteria for the Brugada syndrome: Consensus report
14. Brugada syndrome: Clinical data and suggested pathophysiological mechanism
15. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family
16. + channel mutation causing both long-QT and Brugada syndromes
17. + channel
18. Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome
19. The elusive link between LQT3 and Brugada syndrome: The role of flecainide challenge
20. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes
21. Homozygous premature truncation of the HERG protein: The human HERG knockout
22. Homozygosity for a HERG potassium channel mutation causes a severe form of Long QT syndrome: Identification of an apparent founder mutation in the Finns
23. Homozygous SCN5A mutation in Long-QT syndrome with functional two-to-one atrioventricular block
24. Antagonists to the rescue
25. Pharmacological chaperones: A new twist on receptor folding
26. HERG channel dysfunction in human Long QT syndrome: Intracellular transport and functional defects
27. Kr and trafficking in long QT syndrome
28. Misfolded proteins in the endoplasmic reticulum
29. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive
30. Correction of defective protein trafficking of a mutant HERG potassium channel in human Long QT syndrome: Pharmacological and temperature effects
31. The binding site for channel blockers that rescue misprocessed human Long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations
32. Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators
33. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants